CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced on July 25, 2018 that six U.S. patents have been granted for the compny’s biomimetic platform CMx, which detects circulating tumor cells (CTCs). The patents cover the entire detection workflow, from the capture of very rare CTCs present at fewer than five cells per billion normal cells in early-stage cancer, to the processes ensuring their intact release and identification by means of advanced imaging techniques, allowing CellMax Life to detect CTCs in up to 90 percent of samples. In addition to these six U.S. patents, there are also 16 global patents issued and several additional patents pending in the company’s growing portfolio. “In the past, finding CTCs was not possible in pre-cancer and early-stage cancer, as the cells numbered too few to accurately identify in the bloodstream,” said Shai Friedland, MD, Chief of Gastroenterology & Hepatology, VA Palo Alto Health Care System from the Stanford University School of Medicine. “The CellMax CMx platform’s ability to achieve high sensitivity for pre-cancerous colorectal lesions, while remaining cost-effective and convenient is notable. The CMx platform positions CellMax Life’s CTC test to potentially become a standard option for the 100 million Americans over the age of 45 who are eligible for colorectal cancer screening.” The CellMax CMx platform, has its origins in research conducted on biomimetic smart materials and interfaces by Professor Ying Chih Chang at Stanford University (Professor & Research Fellow, Genomics Research Center, Academia Sinica, Taiwan, Adjunct Professor Stanford University).Login Or Register To Read Full Story